USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Note: This document contains side effect information about colesevelam. Some of the dosage forms listed on this page may not apply to the brand name Welchol.
Common side effects of Welchol include: constipation. Other side effects include: dyspepsia. See below for a comprehensive list of adverse effects.
Applies to colesevelam: oral powder for suspension, oral tablet
Along with its needed effects, colesevelam (the active ingredient contained in Welchol) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking colesevelam:
Incidence not known
Some side effects of colesevelam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to colesevelam: oral powder for reconstitution, oral tablet
The most frequently reported side effects were constipation, dyspepsia, and nausea.
Very common (10% or more): Constipation (up to 11%), flatulence
Common (1% to 10%): Dyspepsia, nausea, vomiting, diarrhea, abdominal pain, abnormal stools, abdominal distension
Uncommon (0.1% to 1%): Dysphagia
Very rare (less than 0.01%): Pancreatitis
Frequency not reported: Intestinal obstruction
Postmarketing reports: Bowel obstruction, esophageal obstruction, fecal impaction, exacerbation of hemorrhoids, pancreatitis
Common (1% to 10%): Hypertriglyceridemia, hypoglycemia
Common (1% to 10%): Hypertension, myocardial infarction, aortic stenosis, bradycardia
Common (1% to 10%): Pharyngitis, rhinitis, nasopharyngitis, upper respiratory tract infection
Common (1% to 10%): Accidental injury, asthenia, flu syndrome/influenza, fatigue, creatine phosphokinase increased
Uncommon (0.1% to 1%): Serum transaminases increased
Common (1% to 10%): Myalgia, back pain
Common (1% to 10%): Headache
Postmarketing reports: Increased seizure activity (resulting from decreased phenytoin levels)
In clinical trials of type 2 diabetes, patient who received this drug as an add on to a sulfonylurea discontinued the trial due to body rash and mouth blistering that occurred on the first day of therapy.
Frequency not reported: Hypersensitivity reaction
Postmarketing reports: Reduced international normalized ration (INR) in patient on warfarin therapy
Postmarketing reports: Increased transaminases
Postmarketing reports: Elevated thyroid-stimulating hormone (TSH) in patients receiving thyroid hormone replacement